BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23936492)

  • 1. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
    Mutsaers HA; Engelke UF; Wilmer MJ; Wetzels JF; Wevers RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
    PLoS One; 2013; 8(8):e71199. PubMed ID: 23936492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.
    Mutsaers HA; Caetano-Pinto P; Seegers AE; Dankers AC; van den Broek PH; Wetzels JF; van den Brand JA; van den Heuvel LP; Hoenderop JG; Wilmer MJ; Masereeuw R
    Toxicol In Vitro; 2015 Oct; 29(7):1868-77. PubMed ID: 26216510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population.
    Snauwaert E; Van Biesen W; Raes A; Glorieux G; Van Bogaert V; Van Hoeck K; Coppens M; Roels S; Vande Walle J; Eloot S
    Nephrol Dial Transplant; 2018 Jun; 33(6):978-986. PubMed ID: 28992139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of CKD on Uremic Toxins and Gut Microbiota.
    Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients.
    Akiyama Y; Kikuchi K; Toyohara T; Mishima E; Suzuki C; Suzuki T; Nakayama M; Tomioka Y; Soga T; Abe T
    Toxins (Basel); 2021 Apr; 13(5):. PubMed ID: 33946481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.
    Zhang ZH; Mao JR; Chen H; Su W; Zhang Y; Zhang L; Chen DQ; Zhao YY; Vaziri ND
    Clin Biochem; 2017 Dec; 50(18):1078-1086. PubMed ID: 28928007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolites Associated With Uremic Symptoms in Patients With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Wulczyn KE; Shafi T; Anderson A; Rincon-Choles H; Clish CB; Denburg M; Feldman HI; He J; Hsu CY; Kelly T; Kimmel PL; Mehta R; Nelson RG; Ramachandran V; Ricardo A; Shah VO; Srivastava A; Xie D; Rhee EP; Kalim S;
    Am J Kidney Dis; 2024 Jul; 84(1):49-61.e1. PubMed ID: 38266973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney and uremic toxin removal: glomerulus or tubule?
    Masereeuw R; Mutsaers HA; Toyohara T; Abe T; Jhawar S; Sweet DH; Lowenstein J
    Semin Nephrol; 2014 Mar; 34(2):191-208. PubMed ID: 24780473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes.
    Wu W; Bush KT; Nigam SK
    Sci Rep; 2017 Jul; 7(1):4939. PubMed ID: 28694431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of uremic solutes in the cerebrospinal fluid in experimental acute renal failure.
    Mair RD; Nguyen H; Huang TT; Plummer NS; Sirich TL; Meyer TW
    Am J Physiol Renal Physiol; 2019 Aug; 317(2):F296-F302. PubMed ID: 31141401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Enlarged Profile of Uremic Solutes.
    Tanaka H; Sirich TL; Plummer NS; Weaver DS; Meyer TW
    PLoS One; 2015; 10(8):e0135657. PubMed ID: 26317986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration.
    Böhringer F; Jankowski V; Gajjala PR; Zidek W; Jankowski J
    ASAIO J; 2015; 61(1):55-60. PubMed ID: 25419832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.
    Niewczas MA; Sirich TL; Mathew AV; Skupien J; Mohney RP; Warram JH; Smiles A; Huang X; Walker W; Byun J; Karoly ED; Kensicki EM; Berry GT; Bonventre JV; Pennathur S; Meyer TW; Krolewski AS
    Kidney Int; 2014 May; 85(5):1214-24. PubMed ID: 24429397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.
    Lim YJ; Sidor NA; Tonial NC; Che A; Urquhart BL
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33668632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and clinical implications of protein-bound uremic toxins.
    Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
    Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Plasma Uremic Solute Levels with Residual Kidney Function in Children on Peritoneal Dialysis.
    Ganesan LL; O'Brien FJ; Sirich TL; Plummer NS; Sheth R; Fajardo C; Brakeman P; Sutherland SM; Meyer TW
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1531-1538. PubMed ID: 34233922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration.
    Mutsaers HA; Wilmer MJ; Reijnders D; Jansen J; van den Broek PH; Forkink M; Schepers E; Glorieux G; Vanholder R; van den Heuvel LP; Hoenderop JG; Masereeuw R
    Biochim Biophys Acta; 2013 Jan; 1832(1):142-50. PubMed ID: 23017367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical Appraisal of Limitations in the Current Definition/Classification of Uremic Toxins.
    Husain-Syed F; Vanholder R; Rosner MH; Kawanishi H; Sirich TL; Ronco C
    Blood Purif; 2023; 52(3):221-232. PubMed ID: 36513030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
    Mutsaers HA; van den Heuvel LP; Ringens LH; Dankers AC; Russel FG; Wetzels JF; Hoenderop JG; Masereeuw R
    PLoS One; 2011 Apr; 6(4):e18438. PubMed ID: 21483698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.